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Abstract
The genetic diversity of HIV-1 across the globe is a major challenge for developing an HIV vaccine. To facilitate immunogen
design, it is important to characterize clusters of commonly targeted T-cell epitopes across different HIV clades. To address
this, we examined 39 HIV-1 clade C infected individuals for IFN-c Gag-specific T-cell responses using five sets of overlapping
peptides, two sets matching clade C vaccine candidates derived from strains from South Africa and China, and three peptide
sets corresponding to consensus clades A, B, and D sequences. The magnitude and breadth of T-cell responses against the
two clade C peptide sets did not differ, however clade C peptides were preferentially recognized compared to the other
peptide sets. A total of 84 peptides were recognized, of which 19 were exclusively from clade C, 8 exclusively from clade B,
one peptide each from A and D and 17 were commonly recognized by clade A, B, C and D. The entropy of the exclusively
recognized peptides was significantly higher than that of commonly recognized peptides (p=0.0128) and the median
peptide processing scores were significantly higher for the peptide variants recognized versus those not recognized
(p=0.0001). Consistent with these results, the predicted Major Histocompatibility Complex Class I IC50 values were
significantly lower for the recognized peptide variants compared to those not recognized in the ELISPOT assay (p,0.0001),
suggesting that peptide variation between clades, resulting in lack of cross-clade recognition, has been shaped by host
immune selection pressure. Overall, our study shows that clade C infected individuals recognize clade C peptides with
greater frequency and higher magnitude than other clades, and that a selection of highly conserved epitope regions within
Gag are commonly recognized and give rise to cross-clade reactivities.
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Introduction
The development of a safe, globally effective and affordable
vaccine offers the best hope for the future control of the HIV
pandemic. One of the major challenges in developing such a
vaccine is the high degree of genetic diversity the virus exhibits.
The extensive genetic variation of HIV is fuelled by high mutation,
recombination and replication rates, partly driven by host cellular
and humoral immune pressure [1,2]. As there is a need to test
vaccines in clinical trials quickly and efficiently, where candidate
vaccines may have been designed for one clade and be tested in
populations where a different clade predominates, the ability to
predict cross-clade epitope coverage is important.
T-cell immunity has been found to play a role in HIV control
[3–5]. The importance of responses to Gag is well documented,
with studies showing that the magnitude of anti-Gag CD8+ T-cell
responses inversely correlates with plasma viral load, [6,7] and that
preferential targeting of this protein during infection leads to lower
viral load [6,8,9]. Other studies have shown that the breadth of
anti-Gag T-cell responses is associated with lower viral loads
[7,10] and collectively, these data strongly implicate Gag as an
important target of HIV-specific T-cells for inclusion in candidate
preventative vaccines. Of major importance for preventative
vaccine development is the identity of regions within the HIV-1
proteome that can be targeted by T-cells and that are cross-
reactive between different viral clades. As several HIV-1 vaccine
candidates are at different stages of development, it is important to
predict whether vaccines based on one clade may be effective in
regions where different clades circulate. Previous studies that
examined cross-clade HIV-1 Gag T-cell immune responses in an
environment of multiple circulating clades [11–13] have found
that HIV-infected individuals can mount robust cross-clade HIV-
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26096specific T-cell immune responses, but with a preference for the
predominant circulating or infecting clade [14,15].
South Africa has a high incidence of HIV-1 and is dominated
by clade C, and a number of phase I and II trials and one phase
IIb efficacy trial have taken place there, testing constructs based on
clade A, B and C-based candidate vaccines [16–18]. Following on
from the first demonstration of vaccine-induced protection from
HIV-1 aquisition in the RV144 trial in Thailand [19], follow-up
trials in high incidence settings such as South Africa are currently
being planned. It is likely that both clade C and non-C based
immunogens will be tested there in the future, and the ability to
predict the level of T-cell coverage and cross-reactivity is thus
important. In this study, we examined intra- and inter-clade cross-
reactivity of HIV-1-specific T-cell responses to Gag, using peptides
matching candidate South African and Chinese clade C vaccine
contructs and compared these with clades A, B and D consensus-
based peptides. The South African and Chinese gag genes have
been included in candidate HIV-1 vaccines that have been tested
for safety in phase I clinical trials [20–22]. We performed this
study using a South African clade C-infected population, where we
sequenced the infecting virus from each individual and assessed T-
cell responses to the different peptide sets. This allowed us to
explore two inter-related aims: a) to identify the location of
commonly and exclusively targeted epitope regions in Gag and
relate these to the level of virus variability; b) to identify the extent
of intra- and inter-clade recognition using peptide sets that match
vaccine inserts.
Results
Participant characteristics
Immunological data were available for 39 participants. The
median age was 28 years (range 22–47 years). The median CD4
count was 492 cells/ml (range 295–1437 cells/ml; Table 1). Thirty-
six participants had a response to at least one Gag peptide from
one of the five peptide sets used. Seventeen participants who had
Human Leukocyte Antigen (HLA) A and B typing data available
(Table S1) had their reactive peptides further characterized.
Genetic distances and epitope coverage between the
infecting virus sequence and peptide sets
We first determined the genetic distance between the peptide
reagents used in the ELISPOT assays and the infecting viral
sequences from each of the participants. All study subjects were
confirmed as being infected with HIV-1 clade C. Genetic distances
for the South African clade CDu422, Chinese clade C, a synthetic
B/C recombinant (CCH) and clade B peptide sets were based on
the full length Gag amino acid sequences, whilst those for the
other clades were based only on the p17p24p2 regions. The
CDu422 and CCH peptide sequences were equally genetically
similar to the infecting viral sequences of the participants studied,
with a median amino acid distance for CDu422 of 5.5%, and for
CCH of 6% (range, 4–15%; Figure 1A). However, the genetic
distance between the peptide sets matching consensus clades B, A
and D with the infecting clade C sequence was significantly greater
(p,0.0001), with median distances of 12%, 13% and 11%,
respectively (Figure 1A).
We next investigated differences in antigenic potential of the
sequences, by examining the proportion of matching T-cell
epitope-length peptides within the infecting viral sequences,
compared to the peptide sets being tested. The coverage of
putative 9mer epitopes within infecting sequences was similar for
CDu422 and CCH (55% and 53% respectively, Figure 1B).
Consistent with the increased amino acid divergence in peptide
sets A, B and D from the infecting virus (Figure 1A), matched
epitope coverage was lower for these peptide sets, at 33%, 30%
and 37%, respectively (Figure 1B). When 9mers were aligned that
differed by one amino acid, there was a similar trend and an
increased frequency of epitope coverage, at 85%, 81%, 63%, 64%
and 71% for peptide sets CDu422,C CH, A, B and D, respectively
(Figure 1B). These data suggest that intra-clade T-cell reactivity
may be similar due to lower genetic divergence compared to
between clades.
Preferential recognition of clade C peptides
At the first level of cross-clade analysis, we wished to identify
whether the magnitude of ELISPOT responses was equally
distributed between the different peptide sets. All comparisons
between peptide sets were based on the p17p24p2 region of the
Gag protein. For the CDu422 and CCH sets, there was no difference
between the median magnitude of response expressed as SFU/10
6
PBMC, at 2690 (range 0 to 24550) for CDu422 and 2828 (range 0
to 19407) for CCH (p.0.05; Figure 2A). Conversely, the
magnitude of responses to other clades was significantly lower,
at 750, 810 and 1390 for clades A, B and D, respectively (p,0.05;
Figure 2A). A similar trend was observed for the breadth of
responses, with a larger median number of reactive peptides being
recognized in the two clade C based peptide reagents, CDu422:4
(range 1–11) and CCH: 4 (range 0–10) when compared to clades A:
1 (range 0–6), B: 2 (range 0–6) and D: 3 (range 0–8) peptide sets
(Figure 2B). Collectively, these data show that peptides more
closely matched to the infecting autologous sequence result in
higher magnitude responses and wider breadth of coverage,
consistent with the predicted epitope coverage shown in Figure 1B.
Peptide variability and cross-reactivity
The second level of analysis consisted of identifying the numbers
of mutually (cross-reactive) and exclusively recognized (recognition
Table 1. Summary of clinical data of study participants.
Characteristic Median (Range)
Age (Years) 28 (22–47)
Plasma HIV RNA (Copies/ml) 11000 (2002260000)
CD4 Count (cells/ml) 492 (295–1437)
Frequency of HIV-specific T-cell responses CDu422 CCH BA D
N( % ) 36 (92) 35 (90) 27 (69) 30 (77) 34 (87)
N (number of participants) = 40. N=39 participants were screened for immunological responses and 36 had responses to at least one Gag peptide. CDu422: South
African clade C, CCH: Chinese clade C; A, B and D are clades A, B, and D sequences.
doi:10.1371/journal.pone.0026096.t001
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reactivity. A total of 84 peptides were recognized by the study
participants, with 29 peptides being exclusively recognized in one
clade only. Nineteen peptides were exclusive to clade C (either
CDu422 or CCH), 8 to clade B, and one peptide each to clades A
and D peptide sets (Figure 3A). Between the two clade C peptide
sets, 6/19 peptides were recognized exclusively in the CDu422
peptide set and 13/19 peptides were common between the two
peptide sets. There were seventeen peptides that were mutually
recognized across all four clades. Of these, 7 were positioned in
p17 and 10 within the p24 region of the Gag protein (Figure 3B).
The remainder of the peptides were recognised in two or three of
the clades.
In an attempt to understand the basis of mutual or exclusive
recognition of peptides, we compared the Shannon entropy score
for the 17 peptides cross-recognized and the 19 peptides
exclusively recognized from the clade C peptide sets (Figure 4A).
It was evident that peptides exclusively recognized had signifi-
cantly higher entropy than the mutually recognized peptides
(p=0.0128). The bulk of these high entropy peptides were also the
least recognized within the cohort (Figure 4B). These data suggest
that exclusive recognition of peptides is related to clade C-specific
variability within the epitopes. Not all peptides exhibited this
pattern of low entropy and mutual recognition or high entropy
and exclusive recognition, and Table 2 shows a representative
example of an individual in the cohort (CC23) recognizing 11
peptides, in some cases despite extensive amino acid variability.
Peptides 63 and 80 are examples of mutually recognized peptides
regardless of amino acid change DRE and TRS within the each
of the peptides, respectively (Table 2). These variations are most
Figure 1. The relationship between infecting viral sequences and peptide amino-acid sequences. (A) Amino acid distances between
infecting viral sequences and ELISpot peptide reagent sequences. The median amino acid distance for each peptide set is represented by a solid line.
Differences were tested for significance by one way ANOVA test and Dunn’s test. (B) Predicted 9mer epitope coverage of two current candidate
vaccine peptide sequences (CDu422 and CCH) and consensus clades A, B, and D peptide sequences. For each peptide set, the values shown in a solid
bar are exact matches while the open bars show coverage when mismatched by 1 amino acid. Analysis was performed using the p17p24p2 Gag
peptides from 39 participants.
doi:10.1371/journal.pone.0026096.g001
Figure 2. Recognition of HIV-1 Gag peptides from clades A, B, CDu422,C CH and D sequences in HIV-1 clade C infected individuals
from South Africa. (A) Total magnitude of Gag-specific T-cells (SFU/10
6 PBMC) against individual peptides for each study individual. Values are
shown in log scale. (B) The minimum number of responses per peptide set for each study individual. Data is based on the p17p24p2 region of the
Gag protein. Significant differences were tested for using one way ANOVA followed by a Dunn’s post-test.
doi:10.1371/journal.pone.0026096.g002
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receptor (TCR) contact residues. In contrast, peptides 7, 15 and 32
were exclusively recognized due to variation in residues important
for recognition, and hence not cross-reactive (Table 2). Peptides
that were reactive despite differences from the infecting viral
sequence may have had variations in ‘tolerated’ residues for
peptide binding and conformation, or the epitopes may indeed
have been presented in infected persons as a result of minor viral
variants that we did not detect by population sequencing of the
dominant virus.
Having observed that mutual or exclusive recognition of variant
peptides was dependent on entropy; we extended the analysis to all
84 peptides in the study, and categorized them into those that were
recognized in 1, 2 or$3 of the peptide variants. Consistent with
the previous data, exclusive peptide recognition was characterized
by significantly higher entropy when compared to recognition in 2
or$3 clades (p,0.05 and p,0.0001, respectively; Figure 4C).
This resulted in a significant negative correlation between the
degree of recognition and peptide entropy (r=20.37, p=0.0005).
The Impact of Host HLA and Epitope Recognition by
HIV-1-specific T-cells
To test the hypothesis that the level of peptide recognition was
most likely governed by mutations in key residues that are
associated with peptide processing and binding to restricting HLA
molecules, we applied an algorithm prediction tool (www.
immuneepitope.org). The tool assesses predicted scores for
Transport Associated with Antigen Processing (TAP) binding (an
estimate of the affinity of the peptide with the TAP molecule),
MHC binding scores (an estimate of the efficiency of binding to an
MHC molecule), proteasome scores (an estimate of cleavage site
usage) and processing scores (an estimate of the quantity of peptide
present in the endoplasmic reticulum that is available for MHC
binding, from a combination of cleavage and transport predic-
tions), and was applied to those participants whose HLA class I A
and B alleles were typed in our study (Table S1) and where
information on these alleles was available in the database. The
total epitope score, which is a summary of the proteasomal, TAP
and MHC scores, as well as the MHC IC50 of the epitopes
restricted by the predicted HLA, are shown in Table S3 (study
individual CC23). There were higher scores for proteasome
activity, TAP and MHC binding, and lower MHC IC50, for
peptide variants that were recognized in the IFN-c ELISPOT
assay. Overall, when peptide variants were classified into those
that were recognized in the ELISPOT assay and those that were
not, the MHC binding score of reactive peptides was significantly
higher than that of non-reactive variants (p,0.0001, Figure 5A).
In addition, proteasomal cleavage scores (Figure 5B), TAP scores
(Figure 5C) and processing scores (Figure 5D) were significantly
higher for reactive peptide variants compared to their non-reactive
counterparts (p=0.0102; p=0.0427 and p=0.0161, respectively).
When all these scores were summated, the total score of the
reactive peptides was significantly higher than non-reactive
peptide variants (p=0.0001, Figure 5E). Furthermore, MHC
IC50 scores of the reactive variants were significantly lower for
reactive variants when compared to their corresponding non-
reactive variants (p,0.0001, Figure 5F). Thus, non-recognized
peptides, with higher entropy, may have at some stage mutated
under immune-mediated selection pressure, showing that vari-
ability in key residues is important for MHC presentation and
Figure 3. Characterisation of HIV-1-specific T-cells recognizing the five peptides sets investigated in the study. (A) The contribution of
each peptide variant to the overall HIV-1-specific T-cell responses in the study. Shown in each subset of the Venn diagram is the number of peptides
recognized in each and overlapping between the four HIV-1 clades. Reactive peptides from all study individuals were combined after removing
overlapping peptides. Each peptide was exclusively assigned to a recognition category depending on the clade in which it was identified. If a peptide
was recognized in more than one category, the category that gave the highest cross-reactivity was considered. The two clade C peptide sets (CDu422
and CCH) were combined. (B) HIV-1 Gag cross-reactive epitope hotspots. The Gag region in which the peptides are located is shown, MBR: membrane
binding region; NLS: nuclear localization signal; CyPA: Cyclophilin A binding region; and MHR: major homology region.
doi:10.1371/journal.pone.0026096.g003
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the notion that different clades of HIV-1 may have been shaped by
class I HLA restricted epitope diversity through probable selective
immune pressures in different populations. However, it cannot be
discounted that the non-reactivity of these peptides might be due
to random sequence variability, unrelated to immune selection,
and that these regions may never be recognized as epitopes.
Discussion
Immunogens designed to elicit T-cell responses are a major
focus of HIV vaccine development. Because of the significant
sequence variation that exists between HIV-1 clades (7–15%,
[23]), there is an acknowledgement that the HIV clades on which
vaccines are based will have an impact on the immune response
elicited, and very likely the subsequent efficacy of vaccines.
Testing HIV-infected persons serves as a proxy for assessing T-
cell cross-reactivity of highly immunogenic vaccines. It is useful for
determining whether HIV-specific responses that particular
populations with specific HLA alleles mount, and their degree of
cross-reactivity to vaccine sequences that may be tested in that
region; infecting viruses represent future ‘challenge’ viruses that
vaccine trial volunteers may encounter. Previous studies have
shown that HIV-infected individuals can mount cross-reactive T-
cell responses against different HIV-1 clades [24–27]. While early
studies focused on a limited number of selected epitopes, and
relied on the use of pools of peptides or cells infected with
recombinant vaccinia virus expressing HIV proteins, more recent
studies have assessed the degree of cross-clade recognition at the
peptide or epitope level [12,28,29]. Ours is the first study to
comprehensively look at the ability of clade C infected individuals
to recognize peptides included in vaccines currently being tested,
and to investigate both intra-clade and inter-clade cross recogni-
tion.
We investigated T-cell reactivity in 39 individuals where the
sequence of the infecting virus was determined by population
sequencing of the dominant virus, and high resolution HLA typing
was performed in a sub-group of these individuals. Although we
did not show directly that responses were due to CD8+ T-cells,
reactivity was assumed to be CD8-mediated as previous studies
have shown that ELISpot responses are predominantly CD8+
T-cell mediated [30,31]. However, we cannot rule out the
possibility that some of the responses may have been CD4-
mediated. In addition, we assessed responses against Gag peptides
from five sequence variants, clade C from South Africa based on
the Du422 sequence [32], CCH (Chinese clade C, for intra-clade
responses), and clades B, A and D, at the single peptide level.
Although South Africa and China have genetically distinct clade C
epidemics, in this study, neither the magnitude nor the breadth of
HIV-specific T-cell responses to Chinese and South African clade
C peptide variants differed significantly. The magnitude and
breadth of the responses to these two clade C peptide variants was
significantly higher than that of Gag peptide reagents based on
clades B, A and D sequences. This is further corroboration of
results from previous studies which have shown that HIV-specific
T-cells are cross-reactive among different HIV clades but with a
Figure 4. Characterization of mutually and exclusively recognized peptides. (A) Comparison of entropy scores between peptides
recognized exclusively by clade C peptide reagents (red) and those mutually recognized in all the four clades tested (purple). (B) Frequency of
responders to epitopes recognized by clade C reagents (red) compared to those mutually recognized in all four clades (purple). (C) Comparison of
entropy score of peptides with different levels of cross-reactivities. Peptides were categorized into those recognized in one (red), two (purple) or
three or more (green) variants of the peptide sets. The non-parametric one way ANOVA and Kruskal-Wallis test was used to test for differences in the
median entropy scores among the different recognition categories.
doi:10.1371/journal.pone.0026096.g004
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Peptide number Name Sequence Restricting HLA SFU/10
6 PBMC
a7 Autologous GKKRYMLKHIVWASRE A*0201
CDu422 KKHYMLKHIVWASRE 1750
CCH KKHYMLKHLVWASRE 940
B GKKKYKLKHIVWASR 0
AK K KYRLKHLVWASRE 0
DK K KYRLKHLVWASRE 0
a11 Autologous EKFALNPGLLETSDG A*0201
CDu422 ERFALNPGLLETSEG 130
CCH ERFALNPGLLETSEG 130
B LERFAVNPGLLETSE 0
AE R F ALNPSLLETAEG 0
DE R F ALNPGLLETSEG 130
15 Autologous KQIIKQLQPALQTGT A*02
CDu422 KQIMKQLQPALQTGT 0
CCH KQIIKQLQPALQTGT 0
BC RQILGQLQPSLQTG 120
A CQQIMEQLQSALKTSE 0
D KQIIGQLQPAIQTGS 0
19 Autologous EELKSLFNTVATLYCV B*0801
CDu422 ELKSLYNTVATLYCV 0
CCH ELRSLFNTVATLYCV 1280
BE ELRSLYNTVATLYC 520
A LKSLFNTVATLYCVH 2353
D ELRSLYNTVATLYCV 480
b32 Autologous SQVSQNYPIVQNLQGQMV Unknown
CDu422 SQNYPIVQNLQGQMV 0
CCH SQNYPIVQNLQGQMV 0
B SQNYPIVQNLQGQMV 0
A KVSQNYALKHRAYEL 0
D SQVSQNYPIVQNLQG 160
38 Autologous NAWVKVIEEKAFSPEI B*4501
CDu422 AWVKVIEEKAFSPEV 470
CCH AWVKVIEEKAFSPEV 470
B NAWVKVVEEKAFSPE 0
A AWVKVIEEKAFSPEV 470
D AWVKVIEEKAFSPEV 470
59 Autologous AGTTSTLQEQIAWMTS A*0201
CDu422 GTTSTLQEQIAWMTS 150
CCH GTTSTLQGQIAWMTS 0
B AGTTSTLQEQIGWMT 0
A GTTSTLQEQIGWMTS 0
D GTTSTLQEQIAWMTS 150
63 Autologous NPPIPVGEIYKRWIIL B*0801
CDu422 PPIPVGDIYKRWIIL 6670
CCH PPVPVGEIYKRWIIL 5980
B NPPIPVGEIYKRWII 5320
A PPIPVGDIYKRWIIL 6670
D PPIPVGEIYKRWIIL 5520
80 Autologous LLTQNANPDCKTILRA B*0801
CDu422 LVQNANPDCKTILRA 7470
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epitope breadth for non-infecting clade peptide sets of approxi-
mately 50–70% was observed in a clade B-infected population
when comparing recognition of clade B peptides to C and A
peptides sets spanning the whole HIV genome [29]. These data
suggest that vaccines based on other clades may be cross-reactive
and therefore warrant their testing in HIV-1 clade C-epidemic
regions. However, whilst vaccines based on non-matching HIV
clades may still induce cross-reactive responses, this reactivity may
be less than that for clade-matched vaccines. Indeed, Gray et al
[16] demonstrated recently in the Phambili phase IIb trial of a
clade B-based Ad5 immunogen in a South African population that
12% fewer vaccinees mounted a response to clade C peptides
compared to clade B, with a 35% reduction in the overall
magnitude of the responses. Whilst the vaccine was not protective
in this population, it was also not effective in a clade B-infected
population [33], so no conclusions can be drawn regarding the
lower clade C-specific responses and vaccine efficacy. Clade-
matching vaccines may represent a viable approach for regions
where single clades circulate, such as Southern Africa, but this
approach is highly limited for regions where multiple clades
circulate, and increasing global HIV-1 diversity is a major
challenge [34]. Thus, the goal of developing a global vaccine that
is as cross-reactive as possible remains.
The results from our study demonstrate that within a single
individual, some HIV peptides were exclusively recognized in the
clade C sequence variants (CDu422 and CCH), whilst others were
uniquely recognized in the clades B, A and D peptide variant. The
recognition of clades B, A and D peptide variants and not the
corresponding clade C peptide variants is of importance, as it
demonstrates that using a single peptide reagent set leads to a
considerable number of responses being missed when investigating
T-cell immune responses [35,36]. These findings are of interest,
since a previous study demonstrated no increase in epitope
recognition when using centre of tree (COT) and most common
recent ancestor (MRCA) peptide sequences in addition to clade B
consensus peptides, in a clade B HIV-infected population [37]. Of
course, all these approaches very likely provide an underestimation
of actual responses, since using peptide reagents matching the
autologous virus demonstrates an increase in detectable T-cell
responses of 29%, even in more conserved parts of the genome
such as p24 [38]. Importantly, a slightly greater increase of 37% in
detectable epitopic regions was demonstrated when using a clade
B Nef PTE (potential T-cell epitope) peptide set compared to clade
B consensus peptides [37]; indeed, preclinical vaccine studies show
that these synthetic mosaic immunogens based on the PTE
approach expand both the breadth and depth of T-cell responses
[39–41]. Whether these increases in cross-reactive breadth are
sufficient to be cross-protective remains to be elucidated in clinical
trials.
Further characterization of reactive peptides in the study
identified highly cross-reactive peptides with low intra- and inter-
clade diversity, as shown by their lower entropy scores. Peptides
that were recognized in two or more variant forms had
significantly lower entropy scores when compared to peptides
recognized once across the peptide sets. The pattern of
recognition observed in the mutually recognized peptides may
imply that HLA alleles restricting these peptides are driving
mutations in the epitopes, as shown by loss of recognition of
certain variants. Further characterization of the mutually
recognized peptides identified other key factors including TAP
and MHC binding and proteasomal cleavage as playing a role in
Peptide number Name Sequence Restricting HLA SFU/10
6 PBMC
CCH LVQNANPDCKTILRA 7470
B LLVQNANPDCKTILK 3920
A LVQNANPDCKSILRA 2653
D LVQNANPDCKTILKA1 2 4 0
89 Autologous GHKARVLAEAMSQVGH A*0201
CDu422 HKARVLAEAMSQTNS 110
CCH HKARVLAEAMSQANG 0
B GHKARVLAEAMSQVT 0
A HKARVLGTGARASVL 0
D HKARVLAEAMSQATN 200
107 Autologous FLGKIWPSHKGRPGN A*0201
CDu422 FLGKIWPSHKGRPGN 450
CCH FLGKIWPSHKGRPGN 450
B FLGKIWPSHKGRPGN 450
A Not available
c N/A
D Not available N/A
aThe previously described HLA allele to restrict the epitope was absent in the individual, however HLA A*0201 was found to be a strong binder to the epitope within
this peptide with a binding affinity of 5 nM for peptide 7 and a weak binder with an affinity of 135 nM for peptide 11, using NetMHC.
bNo epitope described nor predicted to bind to HLA alleles of this participant in this peptide.
cClades A and D had no p15 region of the Gag protein.
Some peptide variants with substitutions in regions flanking the epitope showed discordant recognition patterns regardless of matching epitope sequence, possibly
due to additional non hydrophobic amino acids at the C-terminal or N-terminal that are not well tolerated by class I alleles [63].
ELISPOT reactivity is shown for variants that were reactive, while 0 denotes those that were not reactive. Italicized letters in the peptide sequence indicate amino acid
mismatches between that peptide variant and the CDu422 sequence. The bold letters show amino acid mismatches between the peptide variant sequence and the
infecting virus. The predicted epitope in each variant is underlined. SFU: Spot Forming Units (per 10
6 PBMC).
doi:10.1371/journal.pone.0026096.t002
Table 2. Cont.
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26096Figure 5. Characterization of peptide processing and MHC class I presentation. Comparison of (A) Major Histocompatibility Complex
(MHC) binding score, (B) proteasome cleavage score, (C) transporter associated with antigen processing (TAP) score, (D) processing score, which
combines proteasomal cleavage and TAP transport scores, (E) total epitope score, and (F) MHC IC50, in nM. The total epitope score is a summary of
the proteasomal, TAP and MHC binding scores and between reactive peptide variants (red) and their corresponding non-reactive variants (purple).
Peptides binding to HLA class I A and B alleles had their total processing scores and MHC IC50 predicted using the Immune Epitope Database (www.
immuneepitope.org), and scores were compared using the non-parametric Mann-Whitney test.
doi:10.1371/journal.pone.0026096.g005
Gag Cross-Reactivity to Vaccine Candidates
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26096the recognition of specific variants and not others. This may
illustrate the evolution of HIV due to T-cell pressure in HLA
class I-restricted epitopes [42–47], which is evidenced by HLA
footprints observed in specific regions of the viral proteome
containing HIV-specific HLA class I restricted T-cell epitopes
[48,49]. This phenomenon of HLA-driven viral evolution was
illustrated recently with the first evidence of vaccine-driven T-cell
footprints on viral sequences reported in breakthrough infections
in the STEP trial [47].
Overall, these data further corroborate previous findings which
suggest that within the clades A, B, C and D sequences, some
corresponding viral regions share a similar degree of viral diversity,
possibly due to structural constraints that prevent sequence
mutations in specific parts of the viral genome [50]. This is
further supported by the finding that most of the highly cross-
recognized peptides were from the p24 region of the Gag protein
which is known to be highly conserved and play a structural role in
the HIV proteome. Yet, cross-clade recognition of peptides with
considerable differences in their amino acid composition was also
observed; most of the amino acid changes were semi-conserved,
that is between amino acids with closely related side chains, and
therefore did not have a significant impact on the processing of the
epitopes for presentation by HLA alleles. This suggests that T-cell
receptors of HIV-specific T-cells as well as HLA molecules can
tolerate some degree of amino acid substitution in their epitopes
without total loss of epitope recognition or binding as previously
found in other studies [11,30,51]. Interestingly, even the same
peptide was recognized to different degrees of cross-reactivity in
different individuals, showing that different HLA molecules
tolerate amino acid changes to different extents, which has to be
noted when designing vaccine immunogens to elicit cross-reactive
responses in different populations.
In conclusion, this study has shown that clade C HIV-infected
individuals recognize peptides based on Chinese and South
African sequences equally well, suggesting that intra-clade
variability from diverse geographic regions may not necessarily
be an impediment to vaccine design. Additionally, while
extensive cross-clade recognition was detected, the total
magnitude was lower and the breadth of T-cell recognition
narrower when compared with intra-clade C T-cell responses.
These data suggest that vaccine-induced T-cell immunity of
clade-mismatched vaccines would result in lower immunogenic-
ity at the epitope level. A range of approaches are currently
being pursued to develop cross-reactive HIV vaccines, including
those containing only conserved regions of the HIV proteome
among clades [52–54], as well as mosaic approaches that seek to
represent the majority of the diversity within clades [55].
Immunogens containing conserved regions would serve to focus
the T-cell vaccine-induced response towards regions that are less
likely to mutate due to structural constraints, and specifically
exclude responses to variable regions that may be easily
escapable, have little consequence on viral control, and may
even act as decoys masking responses to conserved regions [56].
The identification in our study of mutually reactive epitopes
within conserved regions of the Gag protein support vaccine
design strategies that incorporate conserved regions of the viral
genome. Alternatively, T-cell mosaic antigens seek to increase
cross-clade reactivity by maximizing the T-cell epitope coverage
for most variants [55]. Ultimately, only testing these different
vaccine approaches in clinical efficacy trials will inform us of
what the best approach is for long-term protection from HIV
acquisition or disease.
Materials and Methods
Ethics Statement
This study was approved by the ethical review boards of the
University of Cape Town and University of the Witwatersrand
and each study participant provided written informed consent.
Participants
Sixty ml of blood was drawn from 40 HIV-1 infected individuals
by venipuncture in Acid-Citrate-Dextrose (ACD) tubes. Eligibility
criteria were willing and able to provide informed consent,
clinically asymptomatic, ART naı ¨ve, and with a peripheral blood
CD4 count above 350 cells/mm
3. Peripheral Blood mononuclear
Cells (PBMCs) were isolated using standard Ficoll-Hypaque
density gradient centrifugation.
Peptides
A total of 540 peptides were used, 120 each for CDu422,C CH
and B and 90 peptides each for the A and D sets used. The clade C
and B peptides spanned the full length of the Gag protein while
clade A and D peptides covered the p17, p24 and p2 regions.
Peptides corresponding to p15 were excluded from data
comparisons between peptide sets because this region was omitted
from the A and D sets. The peptide sets were derived from HIV-1
Gag clades A, D, consensus B, and vaccine insert matched
peptides from CDu422 clade C (South Africa) and a Chinese clade
C strain (CCH). Table S2 details preclinical and clinical trials in
which vaccines containing the CDu422,C CH and A sequences were
tested. All peptides sets were provided by the International AIDS
Vaccine Initiative, apart from the clade B peptides, which were
provided by the National Institute of Health AIDS Research and
Reagent Repository.
HLA typing
High resolution HLA class I A, B and C typing was performed
using sequence specific PCR. Briefly, DNA was extracted using the
QIAGEN DNA isolation kit for blood (QIAGEN, Chatsworth,
CA). High-resolution HLA class I genotyping was performed by
sequencing of exons 2, 3 and 4 using Atria Allele SEQR kits
(Abbott Diagnostics) and Assign SBT 3.5 (Conexio Genomics,
Fremantle, Australia).
Gag sequencing
HIV RNA was extracted from 140ml of frozen plasma by lysis
under highly denaturing conditions followed ethanol washes and
elution in 60ml RNAse-free buffer. HIV gag cDNA was generated
using the Invitrogen Thermoscript
TM RT-PCR system (Invitrogen
Corp, San Diego, CA). cDNA from the RT step was amplified in a
first round PCR using sequence-specific primers, Gag D forward
5’’….39 (HXB2 626-644) and Gag D reverse 59….39 (HXB2 2402-
2382). Three gag regions (A, B and C were amplified separately in
a nested PCR using fragment sequence-specific primers, A
forward 5’’….3’’, HXB2 683-704, A reverse 59….39, HXB2
1303-1282, B forward, HXB2 1226-1248 and B reverse, HXB2
1846-1825, C forward, 1748-1768 and C reverse, 2356-2334 [57].
The amplified products were bulk sequenced in both 59 and 39
directions on an automated ABI 3100 genetic analyser (Applied
Biosystems, Inc) in six separate reactions for each study
participant. The resulting sequences were assembled using
ChromasPro, aligned using BioEdit and phylogenetic analyses
performed using MEGA3.
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T-cell responses were assessed by IFN-c ELISPOT assay as
previously described [8]. Briefly, PBMC were plated in 96-well
polyvinyledene difluoride-backed plates (Microsep; Millipore
Products, France) coated with 250mg of anti-IFN-c mAb 1-D1K
(Mabtech, Sweden) overnight at 4
uC. The unbound antibody was
washed away with three washes with 200ml/well of sterile PBS.
Peptides arranged in 5 pools and 24 matrix pools for each of the
five peptide sets, were added at a final concentration of 1.5mg/ml.
CEF peptide pool (National Institute of Health AIDS Research
and Reference Reagent Program) were added at a final
concentration of 1.5mg/ml. PBMC were added at 100 000 cells/
well and incubated overnight at 5% CO2,37
uC. On the following
day, the plates were washed six times with 200ml/well of PBS
containing 0.05% Tween 20 (PBS-Tween; Sigma, USA). Biotiny-
lated anti-human IFN-c monoclonal antibody (7-B6-1, MabTech
Sweden), diluted to 2mg/ml in PBS-10% FCS, was added and the
plates were incubated for 3 hours at room temperature.
The plates were washed again six times with 200ml/well PBS
0.05% Tween and Streptavidin-Horse-Radish Peroxidase (HRP;
BD Pharmingen, Canada) at 1:500 with PBS-10% FCS was added
for one hour at room temperature. The plates were washed for a
further six times with 200ml/well of PBS-Tween. The development
step was performed with 100ml/well Nova Red substrate (Vector
Laboratories, CA) and stopped by rinsing the plate under tap
water. Spots were counted on a CTL Analyser (CTL Technol-
ogies, Cleveland, USA) and expressed as spot forming units per
million (SFU/10
6) PBMC. A response was considered positive if
the count exceeded 100 SFU/10
6 PBMC after background
subtraction. The criteria for a successful assay was less than 5
SFU in each media control well, no more than 10 SFU for
background wells (cells only) and greater than 400 SFU in the
PHA control wells. Single peptide reactivity was individually
confirmed after deconvoluting the pool/matrix reactive peptides
in the initial screen. The number of epitopes was determined by
taking into consideration overlapping peptides. Two consecutive
peptides were considered as one response and three consecutive
peptides as two responses.
Peptide binding affinity and epitope processing
prediction
Binding affinities in the legend of Table 2 were predicted using
NetMHC3.0 [58,59]. The effect of amino acid mutations on the
different steps involved in epitope processing and presentation by
their respective HLA alleles was investigated by predicting
proteasomal cleavage scores, transport by transport associated
with antigen processing (TAP) and MHC class I binding scores
[60–62] using a computational method (www.immuneepitope.
org). The analysis was performed on all peptides reactive in the
study and the proteasome, TAP, MHC; processing and total
scores were predicted as well as the MHC IC50.
Statistical analysis
Statistical analysis was performed using GraphPad version 5.00
for Windows (Prism Software, San Diego, California USA). All
data were analysed by use of non-parametric statistics. The
Friedman one way ANOVA test for matched pairs was performed
to test for any significant differences in genetic distances,
magnitude and breadth of responses among the different peptide
set. This was followed by a Dunn’s post-test for multiple
comparisons in the case of any significant Friedman p value. All
analyses involving comparison amongst the different peptide sets
are based on p17p24p2 region of the HIV Gag protein. The
Kruskal-Wallis test was performed to test for differences in the
median entropies of peptides in different recognition categories.
The Mann-Whitney test for unmatched pairs was used to test for
significant differences in the total scores and MHC IC50 values
between reactive and non-reactive peptide variants. All tests were
two-tailed and p values of,0.05 were considered significant.
Supporting Information
Figure S1 Characterization of peptides recognized in
the study. (A) Number of individuals responding to each peptide.
(B) Number of peptide variants recognized for each reactive
peptide. (C) Average entropy score of the five peptide variants for
each peptide recognized. The Gag region from which each
reactive peptide is located is shown at the bottom of the figure.
(TIF)
Table S1 Clinical characteristics of study participants.
(DOC)
Table S2 Gag peptide sets and sequences.
(DOC)
Table S3 The effect of amino acid mutations on
predictions of epitope processing.
(DOC)
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